Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
TBI and Increased Risk of Non-Alzheimer’s Disease Dementia in Older Male Twins
Several studies have reported an association between traumatic brain injury(TBI) and increased risk of Alzheimer’s disease(AD) and all cause dementia. Considering the heterogeneous genetic and environmental factors that may contribute to development of dementia, co-twin control analyses provide a level of control for confounding factors that is difficult to achieve with other case-control designs.
Categorized in -
Cognitive Assessment At Medicare’s Annual Wellness Visit In Fee-For-Service And Medicare Advantage Plans
The study provides new insights – the self-reports of survey respondents – into cognitive assessments at annual wellness visits, an area that has been somewhat hidden from view.
Categorized in -
Most Medicare Beneficiaries Say They Don’t Receive Structured Cognitive Assessments at Wellness Visits
The results reinforce the need to evaluate policies and practices around detecting impairment, according to the researchers.
-
Research, Advocacy, and the Fight Against Alzheimer’s
Join Dana Goldman in conversation with Paul Aisen and Lauren Miller Rogen for a discussion about research, advocacy, and bringing awareness to Alzheimer’s.
-
After Decades of Disappointment, a Turning Point Is Visible in Alzheimer’s Treatment
The USC-Brookings Schaeffer Initiative for Health Policy hosted a webinar featuring national thought leaders to examine hopeful signs in clinical development and policy that will ensure access to treatments and diagnostics.
Categorized in -
NIA-Funded Center Addresses Social, Economic Impacts of Alzheimer’s
The new center will explore innovative ways to ease the disease’s toll on individuals, families and caregivers while also developing strategies to reduce its burden on healthcare systems with an international team of researchers.
-
Blood‐Based Biomarkers for Alzheimer’s Pathology and the Diagnostic Process for a Disease‐Modifying Treatment: Projecting the Impact on the Cost and Wait Times
Blood‐based biomarker tests are a promising tool to improve triaging Alzheimer’s disease at the primary care level.
Categorized in -
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for advances in Alzheimer’s disease made in 2001 and projects future breakthroughs over the next 20 years.
Categorized in -
Overcoming Barriers to Success in Alzheimer’s Disease Clinical Trials
Even modest delays in the progression of Alzheimer’s disease could dramatically alter the current trajectory and generate large health benefits.
Categorized in -
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Categorized in